FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	urden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Durso-Bumpus Debra					2. Issuer Name <b>and</b> Ticker or Trading Symbol Blueprint Medicines Corp [ BPMC ]										Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director 10% Owner					
														Ι,	Officer	(give title		Other (s	-	
(Last) (First) (Middle) C/O BLUEPRINT MEDICINES CORPORATION					3. Date of Earliest Transaction (Month/Day/Year) 03/01/2021										below)	below)		below)	below)	
																Chief People Officer				
45 SIDN	EY STREE	ET																		
							4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)															,	led by One	e Repo	orting Perso	n	
CAMBR	IDGE M	IA 	02139											Form filed by More than One Reporting Person						
(City)	(9	State)	(Zip)																	
		Tab	le I - Non	-Deriva	ative	e Se	curities	s Ac	quired	Dis	posed c	of, or	Bene	ficiall	y Owned					
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 5)						es For ally (D) Following (I) (		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D) P		Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)	
Common Stock 03/01				1/2021				A		13,06	3,062 A		\$0	32,567(1)			D			
		-	Table II - [								osed of converti				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, Tr	ansaction ode (Instr.				Expiration	6. Date Exercisable a Expiration Date (Month/Day/Year)		nd 7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
													A	mount						
				c	ode	v	(A)	(D)	Date Exercisa		Expiration Date	Title	N o	umber						
Stock Option (Right to Buy)	\$100.13	03/01/2021			A		26,125		(2)	1	03/01/2031	Comm		6,125	\$0	26,12	5	D		

## **Explanation of Responses:**

- 1. The reported transaction involved the Reporting Person's receipt of a grant of 13,062 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan.
- 2. This option vests with respect to 1/48th of the shares underlying the option on April 1, 2021 and as to an additional 1/48th of the shares underlying the option each month thereafter.

/s/ Christopher Frankenfield, 03/03/2021 Attorney-in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.